Can Vascepa’s FDA review be fast-tracked?
Yes, a company can request an expedited review pathway for an FDA application for Vascepa (icosapent ethyl), but whether it is granted depends on FDA’s criteria and the specifics of the particular application (for example, a new indication, supplemental data, or a new formulation). FDA has multiple mechanisms that can accelerate review, and companies commonly request them when criteria are met.
The FDA’s expedited review options include:
- Priority Review (shortens the review time compared with the standard timeline).
- Accelerated Approval (based on a surrogate endpoint reasonably likely to predict clinical benefit, when applicable).
- Breakthrough Therapy designation.
- Fast Track designation.
- Rolling Review in some circumstances.
These programs are described in FDA’s guidance for expedited development and review. [1][2]
What determines whether FDA says “yes” to fast tracking?
FDA fast-track-related designations are tied to factors such as:
- Whether the product may provide a meaningful advantage over existing therapies.
- Whether the application targets an unmet medical need.
- Whether the proposed endpoint and evidence support a basis for expedited timelines (where relevant to the specific program).
- The quality and completeness of the submission and whether the applicant is prepared to support review without major gaps. [1]
What “fast track” means in practice for review timelines
“Fast Track” and other expedited programs generally aim to shorten the time from submission to key FDA actions, but the exact schedule depends on which pathway is used and what the FDA decides for that particular application. FDA notes accelerated and expedited pathways as ways to speed up development and review when criteria are met. [1][2]
Who can request it, and when does the request happen?
The sponsor (the company developing the application) typically requests expedited programs as the development plan and submission approach are finalized, often around when the FDA can meaningfully evaluate whether the criteria are met. FDA’s expedited program structure is intended to be used during development and at the time of submission to streamline review when justified. [1][2]
Could a new Vascepa-related application be eligible even if earlier versions weren’t?
Yes. Expedited review eligibility can differ from one submission to another. If a later Vascepa application adds a new indication, uses new clinical evidence, or otherwise changes the unmet-need and evidence profile, FDA may evaluate it under the relevant expedited pathway criteria. The determination is not guaranteed just because a prior review was accelerated. [1]
What risks or trade-offs come with expedited review requests?
Expedited pathways can lead to faster decisions, but they do not remove the need for adequate evidence. Some accelerated pathways can rely on surrogate endpoints and may come with post-marketing requirements, depending on the approval route and claims. FDA’s expedited frameworks explain how and when accelerated decisions can happen and under what conditions. [1][2]
Sources
[1] https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review
[2] https://www.fda.gov/media/72055/download